Wednesday, January 16, 2019 7:16:36 AM
“Looking ahead to 2019, it appears likely that the arms race of mega-deals into startups backed by a growing number of mega-funds will continue,” the report said.
Of course we need to see proper funding. And soon.
Would like to see them move forward on their PGT technology. There could be some real potential there.
BATON ROUGE, LA–(July 6, 2016) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to inform shareholders of results of pre-clinical research that support further development of the Company’s patented, novel paclitaxel gallium transferrin (PGT) technology for the treatment of multiple types of cancer.
OncBioMune first tested PGT against a series of human cell lines to evaluate activity in models of breast, colon, lung and three human cell lines of ovarian cancer, including a drug-resistant ovarian cancer model. The results showed PGT to act as an inhibitor of all tumor cell lines, including the drug-resistant ovarian cancer model.
OncBioMune then conducted research to develop an animal model to evaluate the activity of PGT and selected the 4T1 murine mammary carcinoma tumor model. The 4T1 murine mammary carcinoma is recognized as one of the most aggressive cancer cell lines and is known to rapidly metastasize to sites similar to human breast cancer. OncBioMune developed its own 4T1 mouse model and showed an intraperitoneal injection of PGT worked as an inhibitor of 4T1 mammary tumors. Importantly, no gross organ toxicities at necropsy were observed.
http://oncbiomune.com/2016/07/06/oncbiomune-research-shows-activity-of-pgt-technology-in-a-mammary-cancer-animal-model/
"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.
Recent THER News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:29:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/20/2024 08:35:09 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 02/15/2024 10:28:54 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/15/2024 08:00:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 01:10:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 11:28:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 11:17:03 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 12/29/2023 04:26:15 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 09:51:04 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM